FY2029 Earnings Estimate for PolyPid Issued By HC Wainwright

PolyPid Ltd. (NASDAQ:PYPD) – Analysts at HC Wainwright lifted their FY2029 EPS estimates for PolyPid in a research report issued on Thursday, November 12th. HC Wainwright analyst B. Folkes now anticipates that the company will post earnings of $0.87 per share for the year, up from their prior estimate of $0.75. HC Wainwright has a “Buy” rating and a $13.00 price objective on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($0.44) per share. HC Wainwright also issued estimates for PolyPid’s FY2030 earnings at $1.65 EPS.

PolyPid (NASDAQ:PYPD) last issued its quarterly earnings data on Wednesday, November 11th. The company reported ($0.24) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.91 by ($1.15). The firm had revenue of $30.00 million for the quarter, compared to the consensus estimate of $30.00 million.

PYPD has been the subject of a number of other reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of PolyPid in a research note on Friday, September 18th. Oppenheimer assumed coverage on PolyPid in a research note on Tuesday, October 27th. They issued an “outperform” rating and a $10.00 price target on the stock. Craig Hallum set a $12.00 price target on PolyPid in a report on Wednesday, July 22nd. Finally, Wall Street Zen upgraded PolyPid from a “hold” rating to a “buy” rating in a report on Saturday, October 31st. Three analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $11.67.

PolyPid Stock Down 3.0%

Shares of NASDAQ:PYPD opened at $6.40 on Friday. PolyPid has a 12 month low of $3.50 and a 12 month high of $7.15. The company’s fifty day simple moving average is $5.35 and its 200 day simple moving average is $4.79. The firm has a market cap of $122.11 million, a price-to-earnings ratio of -4.74 and a beta of 1.43.

Hedge Funds Weigh In On PolyPid

Several hedge funds have recently made changes to their positions in PYPD. AIGH Capital Management LLC bought a new position in shares of PolyPid during the 2nd quarter worth approximately $7,644,000. ADAR1 Capital Management LLC bought a new stake in shares of PolyPid in the second quarter worth $528,000. Symmetry Peak Management LLC acquired a new position in PolyPid during the second quarter worth $512,000. J. Goldman & Co LP acquired a new position in PolyPid during the second quarter worth $504,000. Finally, Connective Capital Management LLC acquired a new position in PolyPid during the second quarter worth $343,000. 26.47% of the stock is owned by institutional investors.

Latest PolyPid News

These are some of the PYPD news items that stood out recently:

• Positive Sentiment: HC Wainwright reaffirmed its “Buy” rating and set a $13 price target, implying substantial upside from the $6.40 reference price. HC Wainwright ratings
• Positive Sentiment: PolyPid said its D-PLEX₁₀₀ application is under FDA priority review, with a November 28, 2026 PDUFA goal date. The company is preparing for a potential U.S. launch. PolyPid corporate update and Q3 results
• Negative Sentiment: PolyPid reported Q3 2026 EPS of negative $0.24, missing the cited consensus estimate by $1.15. The earnings shortfall is a potential headwind, although investor focus may also center on the upcoming FDA decision. PolyPid quarterly earnings report

PolyPid Company Profile

PolyPid Ltd. (NASDAQ: PYPD) is a clinical-stage biopharmaceutical company focused on developing locally administered therapies designed to provide controlled and sustained drug release at treatment sites. The company’s technology is intended to maintain therapeutic drug concentrations over extended periods while limiting systemic exposure. PolyPid’s lead product candidate is D-PLEX100, an investigational formulation based on doxycycline and the company’s proprietary PLEX polymeric matrix. It is being developed for the prevention of surgical-site infections, initially in patients undergoing colorectal surgery.